In overweight or obese subjects, recombinant human leptin plus pramlintide produced 12.7% mean weight loss, significantly more than either treatment alone.
In plain wordsIn overweight or obese people, leptin plus pramlintide led to more weight loss than either drug alone.
- Peptide
- Pramlintide (Symlin)
- Outcome
- DecreaseBody weight
- Study
n: not reported in source
- Comparator
- Either treatment alone (recombinant human leptin or pramlintide)
- Outcome group
- Body weight · Metabolic and weight
Measurements
- Mean weight loss
- 12.7%
- combination
Source sentences
In a 24-week randomized, double-blind, clinical proof-of-concept study in overweight/obese subjects, coadministration of recombinant human leptin and the amylin analog pramlintide elicited 12.7% mean weight loss, significantly more than was observed with either treatment alone (P < 0.01).
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).